Cellectar Biosciences (CLRB) Insider Trading & Ownership $0.25 -0.04 (-13.54%) As of 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cellectar Biosciences (NASDAQ:CLRB) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage3.70%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$8,400.00Number OfInsiders Selling(Last 12 Months)0 Get CLRB Insider Trade Alerts Want to know when executives and insiders are buying or selling Cellectar Biosciences stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CLRB Insider Buying and Selling by Quarter Cellectar Biosciences Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/10/2025Jarrod LongcorCOOBuy30,000$0.28$8,400.00 (Data available from 1/1/2013 forward) CLRB Insider Trading Activity - Frequently Asked Questions Who is on Cellectar Biosciences's Insider Roster? The list of insiders at Cellectar Biosciences includes Jarrod Longcor. Learn more on insiders at CLRB. What percentage of Cellectar Biosciences stock is owned by insiders? 3.70% of Cellectar Biosciences stock is owned by insiders. Learn more on CLRB's insider holdings. Which Cellectar Biosciences insiders have been buying company stock? The following insider purchased CLRB shares in the last 24 months: Jarrod Longcor ($8,400.00). How much insider buying is happening at Cellectar Biosciences? Insiders have purchased a total of 30,000 CLRB shares in the last 24 months for a total of $8,400.00 bought. Cellectar Biosciences Key ExecutivesMr. James V. Caruso (Age 65)President, CEO & Director Compensation: $1.14MMr. Chad J. Kolean CPA (Age 60)VP, CFO & Secretary Compensation: $711.23kMr. Jarrod Longcor (Age 51)Chief Operating Officer Compensation: $854.24k1 recent tradesMr. Darrell Shane Lea (Age 50)Chief Commercial Officer Dr. Andrei Shustov M.D. (Age 52)Senior Vice President of Medical More Insider Trading Tools from MarketBeat Related Companies FBLG Insider Trades RPTX Insider Trades PEPG Insider Trades IMRX Insider Trades SKYE Insider Trades GANX Insider Trades ICCC Insider Trades CUE Insider Trades VNRX Insider Trades OTLK Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 5 Mid-Cap Stocks Insiders Are Buying This YearInsider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold This page (NASDAQ:CLRB) was last updated on 4/30/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLRB Stock Free CLRB Stock Alerts